1. Home
  2. MRBK vs ACIU Comparison

MRBK vs ACIU Comparison

Compare MRBK & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Meridian Corporation

MRBK

Meridian Corporation

HOLD

Current Price

$18.12

Market Cap

198.4M

Sector

Finance

ML Signal

HOLD

Logo AC Immune SA

ACIU

AC Immune SA

HOLD

Current Price

$3.50

Market Cap

213.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MRBK
ACIU
Founded
2004
2003
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
198.4M
213.3M
IPO Year
2017
2016

Fundamental Metrics

Financial Performance
Metric
MRBK
ACIU
Price
$18.12
$3.50
Analyst Decision
Buy
Strong Buy
Analyst Count
3
2
Target Price
$18.00
$10.00
AVG Volume (30 Days)
81.4K
389.4K
Earning Date
01-23-2026
11-04-2025
Dividend Yield
2.75%
N/A
EPS Growth
75.95
N/A
EPS
1.77
N/A
Revenue
$109,758,000.00
$5,482,957.00
Revenue This Year
$26.84
N/A
Revenue Next Year
$8.90
$644.42
P/E Ratio
$10.27
N/A
Revenue Growth
18.84
N/A
52 Week Low
$11.16
$1.43
52 Week High
$18.33
$4.00

Technical Indicators

Market Signals
Indicator
MRBK
ACIU
Relative Strength Index (RSI) 67.54 55.11
Support Level $17.05 $3.32
Resistance Level $17.91 $3.80
Average True Range (ATR) 0.44 0.24
MACD -0.02 0.02
Stochastic Oscillator 88.16 56.34

Price Performance

Historical Comparison
MRBK
ACIU

About MRBK Meridian Corporation

Meridian Corp is a bank holding company. Through its banking subsidiary, it operates as a full-service, state-chartered commercial bank providing personal, business lending, and deposit services. It operates in three reportable segments including Bank, Wealth, and Mortgage. The company generates maximum revenue from the Bank segment which consists of commercial and retail banking. It generates interest income from its lending (including leasing) and investing activities and is dependent on the gathering of lower-cost deposits from its branch network or borrowed funds from other sources for funding its loans.

About ACIU AC Immune SA

AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

Share on Social Networks: